Antithyroid drug side effects in the population and in pregnancy

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 4, 2016, Pages 1606-1614

  Andersen, Stine Linding ^a   Olsen, Jørn ^b   Laurberg, Peter ^a,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; PROPYLTHIOURACIL; THIAMAZOLE; ANTITHYROID AGENT;

ADULT; AGRANULOCYTOSIS; ARTICLE; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTHYROIDISM; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREGNANCY; PRESCRIPTION; PROGENY; RELAPSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT; ABNORMALITIES, DRUG-INDUCED; CHEMICALLY INDUCED; PATHOLOGY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE;

ABNORMALITIES, DRUG-INDUCED; ADULT; AGRANULOCYTOSIS; ANTITHYROID AGENTS; FEMALE; HUMANS; HYPERTHYROIDISM; LIVER FAILURE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; YOUNG ADULT;

EID: 85011317613     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-4274     Document Type: Article

References (38)

1. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1:238-249.
2. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98:4373-4381.
3. Bahn RS, Burch HB, Cooper DS, et al. American Thyroid Association, American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593-646.
4. Stagnaro-Green A, Abalovich M, Alexander E, et al. American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081-1125.
5. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2543-2565.
6. Milham SJ, Elledge W. Maternal methimazole and congenital defects in children. Teratology. 1972;5:125-126.
7. Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014;10:1533-1540.
8. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905-917.
9. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009;94:1881-1882.
10. Glinoer D, Cooper DS. The propylthiouracil dilemma. Curr Opin Endocrinol Diabetes Obes. 2012;19:402-407.
11. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull. 1998;45:320-323.
12. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53:441-449.
13. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38-41.
14. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
15. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid. 2004;14:459-462.
16. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009;19:559-563.
17. Watanabe N, Narimatsu H, Noh JY, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50 385 patients with Graves' disease. J Clin Endocrinol Metab. 2012;97:E49-E53.
18. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013;98:4776-4783.
19. Kobayashi S, Noh JY, Mukasa K, et al. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid. 2014;24:796-801.
20. Kim HK, Yoon JH, Jeon MJ, et al. Characteristics of Korean patients with antithyroid drug-induced agranulocytosis: a multicenter study in Korea. Endocrinol Metab (Seoul). 2015;30(4):475-480.
21. Akmal A, Kung J. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. Expert Opin Drug Saf. 2014;13:1397-1406.
22. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014;78:619-629.
23. Yang J, Li LF, Xu Q, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid. 2015;25:278-283.
24. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. 2012;97:4549-4558.
25. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol (Oxf). 2016;84(1):115-120.
26. Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396-2403.
27. Laurberg P, Andersen SL. Antithyroid drug use in early pregnancy and birth defects. Time windows of relative safety and high risk? Eur J Endocrinol. 2014;171:R13-R20.
28. Andersen SL, Laurberg P. Antithyroid drugs and congenital heart defects: ventricular septal defect is part of the methimazole/carbimazole embryopathy. Eur J Endocrinol. 2014;171:C1-C3.
29. Momotani N, Hisaoka T, Noh J, Ishikawa N, Ito K. Effects of iodine on thyroid status of fetus versus mother in treatment of Graves' disease complicated by pregnancy. J Clin Endocrinol Metab. 1992;75:738-744.
30. Yoshihara A, Noh JY, Watanabe N, et al. Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. Thyroid. 2015;25:1155-1161.
31. Taylor PN, Vaidya B. Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyrotoxicosis in pregnancy. Eur Thyroid J. 2012;1:176-185.
32. Yoshihara A, Noh JY, Watanabe N, et al. Frequency of adverse events of antithyroid drugs administered during pregnancy. J Thyroid Res. 2014;2014:952352.
33. Lo JC, Rivkees SA, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid. 2015;25:698-705.
34. Bernal J, Nunez J. Thyroid hormones and brain development. Eur J Endocrinol. 1995;133:390-398.
35. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. Eur J Endocrinol. 2004;151:U25-U37.
36. Andersen SL, Olsen J, Wu CS, Laurberg P. Low birth weight in children born to mothers with hyperthyroidism and high birth weight in hypothyroidism, whereas preterm birth is common in both conditions: a Danish National Hospital Register study. Eur Thyroid J. 2013;2:135-144.
37. Andersen SL, Olsen J, Wu CS, Laurberg P. Spontaneous abortion, stillbirth and hyperthyroidism: a Danish population-based study. Eur Thyroid J. 2014;3:164-172.
38. Andersen SL, Olsen J, Laurberg P. Foetal programming by maternal thyroid disease. Clin Endocrinol (Oxf). 2015;83:751-758.